It’s possible that GLP-1s may be useful for a range of substance use disorders, including opioid use disorder and nicotine ...

A new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol.

GLP-1) receptor agonists, which are used to treat type 2 diabetes and/or obesity, were linked to vision problems in a small ...

Weekly treatment with low doses of the GLP-1 receptor agonist semaglutide (Ozempic) reduced alcohol consumption and craving ...

In a world where alcohol claims nearly 178,000 lives annually in the U.S. alone, a glimmer of hope has emerged from an ...

Q1 2025 Earnings Call Transcript February 13, 2025 Veru Inc. beats earnings expectations. Reported EPS is $-0.06, ...

Semaglutide, used for diabetes and obesity, may reduce alcohol cravings in adults with alcohol use disorder, offering a potential solution to a major treatment gap.

Semaglutide prescription initiation predictors included female sex and use of antidepressants among patients with obesity without diabetes.

Medications that have transformed the treatment of obesity may also help people drink less alcohol, according to new government-funded research.

As drugs like Ozempic and Mounjaro continue to skyrocket in usage, doctors are encountering more and more cases linking them ...

A game-changer for obesity and heart failure? Dr Pandey reveals breakthrough GLP-1 trial results that show reduced cardiovascular risk and better outcomes for HFpEF patients. Don’t miss this!